Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis

作者: Scott A. Fink , Ira M. Jacobson

DOI: 10.1038/NRGASTRO.2011.57

关键词: CirrhosisInternal medicineAdverse effectLiver transplantationMedicineHepatitis CHepatitis BGastroenterologyExacerbationDecompensationHepatocellular carcinoma

摘要: Treatment of patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis should focus on controlling the complications cirrhosis, surveillance for hepatocellular carcinoma and, if applicable, preparation orthotopic liver transplant. Interferon-based regimens treatment hepatitis C have been somewhat successful in although be approached caution. Given potential exacerbation decompensation and poor tolerance adverse effects, reserved those awaiting transplantation. Eradication HCV before transplantation reduces chances recurrent infection after HBV can treated few effects cirrhosis. This is associated improvement some patients. Hepatocellular remains a significant risk all control eradication does not remove this risk.

参考文章(51)
G. T. EVERSON, L. BALART, S. S. LEE, R. W. REINDOLLAR, M. L. SHIFFMAN, G. Y. MINUK, P. J. POCKROS, S. GOVINDARAJAN, E. LENTZ, E. J. HEATHCOTE, Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Alimentary Pharmacology & Therapeutics. ,vol. 27, pp. 542- 551 ,(2008) , 10.1111/J.1365-2036.2008.03620.X
Kausik Das, Kshaunish Das, Simanti Datta, Suparna Pal, Jaba Ranjan Hembram, Gopal Krishna Dhali, Amal Santra, Abhijit Chowdhury, Course of disease and survival after onset of decompensation in hepatitis B virus‐related cirrhosis Liver International. ,vol. 30, pp. 1033- 1042 ,(2010) , 10.1111/J.1478-3231.2010.02255.X
Savino Bruno, Massimo Zuin, Andrea Crosignani, Sonia Rossi, Felice Zadra, Luigi Roffi, Mauro Borzio, Alessandro Redaelli, Alberto Chiesa, Enrico Maria Silini, Piero Luigi Almasio, Patrick Maisonneuve, Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. The American Journal of Gastroenterology. ,vol. 104, pp. 1147- 1158 ,(2009) , 10.1038/AJG.2009.31
Y.-F. Liaw, C.-M. Lee, R.-N. Chien, C.-T. Yeh, Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. Journal of Viral Hepatitis. ,vol. 13, pp. 250- 255 ,(2006) , 10.1111/J.1365-2893.2005.00687.X
Jose A. Carrión, Eva Martínez-Bauer, Gonzalo Crespo, Santseharay Ramírez, Sofia Pérez-del-Pulgar, Juan Carlos García-Valdecasas, Miquel Navasa, Xavier Forns, Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. Journal of Hepatology. ,vol. 50, pp. 719- 728 ,(2009) , 10.1016/J.JHEP.2008.11.015
Jeffrey S Crippin, Tim McCashland, Norah Terrault, Patricia Sheiner, Michael R Charlton, A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transplantation. ,vol. 8, pp. 350- 355 ,(2002) , 10.1053/JLTS.2002.31748
Robert J Fontana, Arun J Sanyal, Marc G Ghany, William M Lee, Andrea E Reid, Deepa Naishadham, Gregory T Everson, Jeffrey A Kahn, Adrian M Di Bisceglie, Gyongyi Szabo, Timothy R Morgan, James E Everhart, HALT–C Trial Group, Factors That Determine the Development and Progression of Gastroesophageal Varices in Patients With Chronic Hepatitis C Gastroenterology. ,vol. 138, pp. 2321- 2331 ,(2010) , 10.1053/J.GASTRO.2010.02.058
Michael Charlton, Eric Seaberg, Russell Wiesner, James Everhart, Rowen Zetterman, John Lake, Katherine Detre, Jay Hoofnagle, Predictors of patient and graft survival following liver transplantation for hepatitis C Hepatology. ,vol. 28, pp. 823- 830 ,(1998) , 10.1002/HEP.510280333